cardiac cta image

COVID-19 Treatment Information

Registration for COVID-19 monoclonal antibody treatment is not available in Broward Health’s emergency rooms and is by appointment only. To schedule an appointment for monoclonal antibody treatment for COVID-19, you must:

  1. Have a referral from a primary care physician
  2. Have a positive COVID-19 PCR or Rapid Test result
  3. Meet Centers for Disease Control and Prevention criteria.

To verify if you are eligible, call Broward Health’s free, 24/7 Nurse Connect line to speak with a registered nurse: 954-320-5730.

Additional information on COVID-19 treatment and how to get it is available on the Florida Department of Health COVID-19 response page. If you are experiencing a medical emergency, call 9-1-1 or visit the emergency room.

For Patients: 

Monoclonal antibody treatments may help people fight mild to moderate COVID-19 infections by easing symptoms and preventing hospitalization. Broward Health is pleased to partner with community physicians to expand access to monoclonal antibody treatment for qualifying patients receiving care outside of the Broward Health system. The treatment is provided at no cost to the patient and consists of a 30-minute infusion, followed by a one-hour post observation period. To be scheduled, eligible patients must have a physician referral and be approved for treatment.

Broward Health currently offers casirivimab/imdevimab (REGEN-COV) monoclonal antibody therapy. The U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for the unapproved products casirivimab and imdevimab administered together for the treatment of mild to moderate COVID-19 in qualifying adults and pediatric patients.

Please review the EUA fact sheet for more information on the treatment and consult with your healthcare provider to determine if you are a candidate. This treatment is most effective when given immediately following COVID-19 diagnosis. This information is provided as a community education resource.

COVID clinical trials

For Providers 

Broward Health has expanded ordering access to casirivimab/imdevimab (REGEN-COV) monoclonal antibody therapy for the treatment of certain cases of mild to moderate COVID-19. Community physicians and APRNs who are not on staff at Broward Health may order casirivimab and imdevimab combination therapy.

 

The U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) to permit the emergency use of the unapproved products casirivimab and imdevimab administered together for the treatment of mild to moderate COVID-19 in adults and pediatric patients with positive results of direct SARS-CoV-2 viral testing who are 12 years of age and older weighing at least 40 kg, and who are at high risk for progressing to severe COVID-19 and/or hospitalization.

 

Please review the EUA, order form, and letter to ordering physicians and APRNs who are not credentialed at Broward Health.